Kenvue (KVUE) Projected to Post Earnings on Thursday

Kenvue (NYSE:KVUE - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of $0.23 per share and revenue of $3.69 billion for the quarter. Kenvue has set its FY 2025 guidance at 1.440-1.469 EPS.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, analysts expect Kenvue to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kenvue Trading Up 0.1 %

KVUE stock traded up $0.02 during mid-day trading on Friday, reaching $23.98. The company's stock had a trading volume of 14,097,083 shares, compared to its average volume of 17,031,836. The company has a market cap of $46.01 billion, a price-to-earnings ratio of 45.25, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. Kenvue has a 12 month low of $17.67 and a 12 month high of $24.46. The business's 50 day moving average price is $23.09 and its 200 day moving average price is $22.50. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be given a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.42%. Kenvue's dividend payout ratio (DPR) is presently 154.72%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on KVUE. Canaccord Genuity Group increased their target price on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. UBS Group lowered their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Evercore ISI started coverage on Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 price objective for the company. Barclays cut their price target on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a report on Monday, April 14th. Finally, Citigroup increased their price target on Kenvue from $21.00 to $22.00 and gave the company a "neutral" rating in a research report on Monday, April 14th. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $24.42.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.